Related Experiment Video
Updated: Sep 18, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
[Pharmacoeconomics of the New Antidepressants and Antipsychotics]
1Bezirksklinikum Gabersee, Fachkrankenhaus für Psychiatrie, Psychotherapie und Neurologie, Wasserburg a. Inn. g.laux.bzk-gabersee@t-online.de
Abstract:
This review summarizes results of cost-utility analyses done with newer versus older antidepressants as well as atypical versus conventional/typical neuroleptics/antipsychotics. Following descriptions of the methodological principles, the currently available studies (simulation models) are presented and discussed critically. It can be stated that the economic value of different antidepressants and the atypical neuroleptics can not be decided definitively at the present time due to methodological reasons (e. g. lacking of randomized prospective studies). Increased quality of life of patients and their family seems true for the newer psychotropics, measurement is difficult, however, and a challenge for social and ethical discussions.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents